If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today.
Theme | Project | Modality | Stage |
---|---|---|---|
Cancer | Next generation DC therapy | Cell therapy | Hit-to-Lead |
Cancer | High affinity dual-specificity biologics | Cell therapy | Hit Discovery |
Cancer | Safer CAR-T cells | Cell therapy | Hit Discovery |
Immunology and inflammation | pDC therapy for lupus | Inhibitor | Hit Discovery |
Immunology and inflammation | A therapy for haemolytic disease | Biologic | Hit Discovery |
Immunology and inflammation | Antioxidant enzyme | Biologic | Hit Discovery |
Immunology and inflammation | Improving T cell memory | Vaccine, Biologic | Target Validation |
Global health and infection | VirPRO – targeting Mpro | Inhibitor | Hit-to-Lead |
Global health and infection | VirDUB – targeting PLPro | Inhibitor | Hit-to-Lead |
Global health and infection | P. vivax diagnostic | Diagnostic | Hit-to-Lead |
Global health and infection | Toxoplasma Vaccine | Vaccine | Hit Discovery |
Neurological disorders | Precision epigenetics | Inhibitor | Hit-to-Lead |
Neurological disorders | Inhibitors of apoptosis | Inhibitor | Hit Discovery |
Platform technologies | E3 ligase warheads/ACTT | Protein degrader | Hit Discovery |
Platform technologies | IL-11 signaling / Nelcanen | Biologic, inhibitor | Hit Discovery |
Platform technologies | BioTACs/ Proxima Bio | Biologic, degrader | Hit Discovery |
Digital health | Genomic orchestration engine | Software | Successful pilots with 5 Victorian laboratories |
Digital health | Animal management system | Software | Currently used by 3 external animal research institutions |